Medical - Diagnostics & Research · NASDAQ
Current Price
$573.82
Intrinsic Value
Use the calculator below to estimate
Run a PE ratio stock valuation on IDEXX Laboratories, Inc. with auto-filled earnings data, adjustable target PE, and instant fair value estimate.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Earnings Yield
2.31%
ROE (TTM)
69.8%
Based on trailing twelve-month data, IDXX has earnings per share of N/A and trades at a PE ratio of N/A. These are key inputs for stock valuation using the PE ratio method.
The trailing twelve-month PE ratio of IDXX is available in the calculator. This stock valuation metric shows how much investors pay per dollar of IDEXX Laboratories, Inc.'s earnings. Use MiniValuator's PE ratio calculator for detailed analysis.
Whether IDXX is overvalued depends on comparing its PE ratio to industry peers, historical averages, and growth expectations. A PE ratio above the sector average may indicate overvaluation, but high-growth companies often justify higher PE ratios. Run a full stock valuation on MiniValuator to analyze.
To value IDXX using PE ratio: compare its current PE to the sector average, analyze the PEG ratio for growth-adjusted stock valuation, check historical PE ranges, and estimate fair value by multiplying target PE by EPS. MiniValuator's PE ratio calculator automates this analysis.
The PEG ratio of IDXX is available in the calculator. PEG ratio divides the PE ratio by the earnings growth rate — a PEG below 1.0 may suggest the stock is undervalued relative to its growth, making it a useful complementary stock valuation metric.
PE ratio provides quick relative stock valuation — how IDXX compares to peers. DCF provides absolute stock valuation — what the stock is worth based on projected cash flows. For comprehensive stock valuation, use both methods together. MiniValuator offers both PE and DCF calculators.
